Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?

Prostate-specific membrane antigen (PSMA) expression has been shown in neovasculature of various malignancies. Recurrent medullary thyroid cancer (MTC) is difficult to treat. We present the findings on PSMA-positron emission tomography/computed tomography (PET/CT) of a 68-year-old man with MTC, who...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Saurabh, Prabhu, Meghana, Damle, Nishikant Avinash, Bal, Chandrasekhar, Kumar, Praveen, Nalla, Harish, Arun Raj, Sreedharan Thankarajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Interesting Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011559/
https://www.ncbi.nlm.nih.gov/pubmed/29962733
http://dx.doi.org/10.4103/ijnm.IJNM_10_18
Descripción
Sumario:Prostate-specific membrane antigen (PSMA) expression has been shown in neovasculature of various malignancies. Recurrent medullary thyroid cancer (MTC) is difficult to treat. We present the findings on PSMA-positron emission tomography/computed tomography (PET/CT) of a 68-year-old man with MTC, who presented with a recurrent left paratracheal mass and rising calcitonin. The scan revealed significant uptake on PSMA imaging but not on (68)Ga-DOTANOC PET/CT. (177)Lu-PRRT is one of the therapeutic options in patients with recurrent MTC, but in this case was not possible due to lack of somatostatin receptor expression. Imaging evidence of PSMA expression alerts us to the potential use of (177)Lu-DKFZ-PSMA-617 therapy in such patients.

Ejemplares similares